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E-mail address: oferm@ekmd.huji.ac.il (O. MandelHuman natural killer (NK) cells possess an arsenal of receptors programmed to regulate the NK cell
functions, once encountering a target cell. In general, the activating receptors mediate cytotoxicity
when engaged by their tumor speciﬁc, stress induced, virally encoded, or rarely, self ligands.
Whereas, the inhibitory receptors bind self molecules, mostly MHC class I, presented on all normal
and healthy nucleated cells. However, NK cells also possess numerous, highly homologous, pairs of
receptors that sometimes even share the same ligands but display divergent functions. In this
review we describe the NK cell repertoire of paired receptors and discuss questions regarding their
function and mode of action. We focus primarily on the three PVR-binding receptors; the co-stim-
ulatory DNAM1 and CD96 and the inhibitory TIGIT.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Paired inhibitory and activating NK cell receptors
NK cells, which belong to the innate immune system, are able to
quickly kill virally infected and malignant cells. The complicated
repertoire of activating and inhibitory receptors that regulate NK
activity helps to ensure that NK cells would be able to efﬁciently
kill invading pathogens but not normal self cells [1]. The differ-
ences in the function of the inhibitory and activating NK cell recep-
tors are reﬂected by the different ligands recognized by the various
receptors. While the activating NK cell receptors recognize patho-
gen-derived, stress-induced, tumor speciﬁc and surprisingly some-
times even self ligands, the inhibitory receptors, in general,
recognize self proteins, mainly MHC class I [2]. The differences in
the inhibitory and activating ligands repertoire probably exist to
guarantee the discrimination between self and non-self. Therefore,
it was surprising to discover the existence of pairs of highly homol-
ogous proteins that in some cases even share the same ligands, but
display divergent functions (Table 1). In this review we discuss the
properties of the various members of the human paired NK recep-
tors and mainly focus on reviewing the activity of the PVR-binding
receptors in an attempt to better understand the biological func-
tion of the paired receptors.
2. Paired receptors: MHC class I binding proteins
Most of the paired receptors belong to the killer cell immuno-
globulin-like receptors (KIR) family. This family includes inhibitorychemical Societies. Published by E
boim).receptors with a long intra cytoplasmic domain containing a vari-
able number of immunoreceptor tyrosine-based inhibitory motifs
(ITIM), and activating or co-activating receptors, with a nearly
identical extracellular region containing shorter intra cytoplasmic
domain which lacks ITIMs (Table 1). These short killer activating
receptors (KAR) also display a unique transmembrane sequence,
which contains a charged amino acid that interacts with an activat-
ing adaptor molecule [3].
The ligands of most of the KARs are unknown (Table 1) and
most of the known KAR ligands are MHC class I proteins which
are also recognized by their KIR inhibitory counterparts. For exam-
ple, both the inhibitory KIR2DL1 and its activating counterpart
KIR2DS1 bind HLA-C molecules containing a lysine residue at posi-
tion 80 ((HLA-CLys80, Table 1) and [4,5]). Inhibitory KIR2DL2/3 and
activating KIR2DS2 bind HLA-C proteins containing an asparagine
residue at position 80 ((HLA-CAsn80, Table 1) and [4,6]). In both
cases and in all other examples in which the same ligand is recog-
nized by the KIR and the KAR, the binding of the inhibitory recep-
tors is always stronger (Table 1).
As mentioned above, the ligands of many KARs are still un-
known. One notable example of a distinctive KAR that has no
known ligands is KIR3DS1, which correlates with better prognosis
of HIV-infected individuals [7,8]. Although this receptor possesses
an almost identical extracellular domain to that of its inhibitory
KIR3DL1 counterpart [9], there is no direct evidence that KIR3DS1
can indeed interact with MHC class I proteins [9].
An example of paired receptors was also noted in the C-type
lectin family of receptors. The CD94/NKG2A constitutes an inhibi-
tory receptor, while its counterpart CD94/NKG2C that lacks ITIMs,lsevier B.V. All rights reserved.
Table 1
Paired receptors on human NK cells.
Receptor ITIM Ligand Relative
afﬁnity
Signal Ref.
KIR2DL1 2 HLA-CLys80 High  [4,5]
KIR2DS1 0 HLA-CLys80 Low +
KIR2DL2 2 HLA-CAsn80
HLA-CLys80?
HLA-B?
High  [6,65]
KIR2DS2 0 HLA-CAsn80 Low +
KIR2DL3 2 HLA-CAsn80
HLA-CLys80?
HLA-B?
 [65]
KIR2DS3 0 ? +
KIR2DL4 1 HLA-G ± [22,23,66]
KIR2DS4 0 HLA-Cw4
A non-HLA
ligand
+ [15,67]
KIR2DL5 2 ?  [68]
KIR2DS5 0 ? + [69]
KIR3DL1 2 HLA-Bw4
HLA-Bw6?
 [70–72]
KIR3DS1 0 HLA-Bw4? + [7,8]
KIR3DL2 2 HLA-A3,A11  [73]
KIR3DL3 1 ? ?
CD94/
NKG2A
2 HLA-E High  [10]
CD94/NKG2C 0 HLA-E Low +
CD300a 4 ?  [19]
CD300c 0 ? +
DNAM1/
CD226
0 PVR/CD155 114–119 nM + [49]
Nectin2/CD112 Low
Tactile/CD96 1 PVR/CD155 37.6 nM +
TIGIT/
WUCAM
1 PVR/CD155 1–3 nM 
Nectin2/CD112 Low
Nectin3/CD113 38.9 nM
The table shows the paired receptors expressed on NK cells. The number of
immunoreceptor tyrosine-based inhibitory motifs (ITIM) is indicated. When ligands
were identiﬁed, they are indicated, otherwise they are marked with ‘‘?”.  repre-
sents negative inhibitory signal, whereas + indicates positive activating signal.
When the binding afﬁnity is known, it is indicated (Kd). Otherwise, the strength of
the signal mentioned is relative to its inhibitory counterpart.
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ble 1 and [10]).
Because the KAR interactions with their ligands seem to be
weak compared to their inhibitory counterparts, it is quite difﬁcult
to make a general conclusion that indeed the MHC class I proteins
are the ligands of the various KARs. Alternatively, it is quite possi-
ble that the binding of the various KARs to the MHC class I proteins
is weak because the MHC class I proteins are not the ‘‘real” KAR li-
gands. Indeed, one of the puzzling questions in the ﬁeld with this
regard is why should NK cell develop killer receptors against self
MHC class I proteins? One possible explanation is that the KARs
are more sensitive to the peptide repertoire presented by a given
MHC class I protein. Thus, when the cells are infected with a cer-
tain pathogen, the peptide repertoire is slightly changed and this
change might be better recognized by the KARs. Indeed, it was
shown that peptides could affect the recognition by inhibitory
receptors [6,11] and could even antagonize the inhibitory receptor
function [12]. Nevertheless, it is a bit difﬁcult to assume that the
small changes in the peptide repertoire of infected cells (that often
are limited to less than 1%) would have a dramatic effect on the
KAR versus KIR recognition. With that regard, although Fadda
et al. [12] elegantly demonstrated an antagonistic effect of certain
peptides on KIR mediated inhibition, the lowest ratio they have
used in their work was 10% antagonistic to 90% inhibitory peptides.
We think, that a ratio of 1% antagonistic to 99% inhibitory peptideswould probably imitate better physiological situations. It will be
interesting to test whether in the context of ‘‘real infection” pep-
tide antagonism could be observed. Finally, the observations indi-
cating that a single KIR could recognize many different MHC
proteins, which contain different peptide repertoire, suggest a min-
or role for peptides in the KIR recognition ([4] and Table 1).
It also might be possible that the KARs ‘‘sharpen” the threshold
needed for NK cell inhibition and activation. The KIRs binds their
cognate MHC class I proteins with a very fast on and off rates
[13] and indeed it was demonstrated that different levels of HLA-
C proteins determines the efﬁciency of NK cell inhibition [14].
Thus, it is possible that when the MHC class I protein is also en-
gaged by KAR, which provides a counterbalance activating signal,
the inhibitory threshold is better deﬁned.
Alternatively, however, because the KAR binding to MHC class I
is of such low afﬁnity it is possible that the ‘‘true” ligands of the
KARs are not the MHC class I proteins but other tumor-speciﬁc
or pathogen-derived ligands. Supporting this possibility, we have
demonstrated that KIR2DS4 recognizes an unknown melanoma li-
gand [15]. A further support to this hypothesis comes from the
mouse Ly49I and Ly49H pair. It was shown in mice that the inhib-
itory Ly49I receptor and its highly homologous activating counter-
part, Ly49H, share the same ligand; the m157 protein, which is
encoded by the mouse cytomegalovirus [16]. The explanation gi-
ven to the existence of this pair is that the mouse CMV originally
used the Ly49I receptor to escape NK cell attack through the inter-
action with m157, while NK cells responded back through the
development of a very similar activating receptor (Ly49H) that rec-
ognizes the same ligand [16].3. Paired receptors: non-MHC class I binding proteins
In addition to MHC class I binding receptors, inhibitory recep-
tors that bind ligands other than MHC class I proteins are also pres-
ent on NK cells [17]. It is still unclear why these receptors are
needed to operate under normal conditions, when every nucleated
cell expresses MHC class I proteins. A possible explanation might
be to provide an additional inhibitory mechanism against the
KAR–MHC class I interactions. However, this explanation is proba-
bly unlikely since similarly to the KIRs, the non-MHC class I bind-
ing inhibitory receptors also have activating counterparts. For
instance, while CD300a contains 4 ITIMs in its cytoplasmic tail,
CD300c (which shows 80% identity to CD300a at the extracellular
Ig domain) is considered to be an activating receptor. Indeed, the
transmembrane region of CD300c contains an unusual charged
glutamic acid residue and a short cytoplasmic tail [18]. These
two receptors are very similar and all new 13 different mAbs that
were generated against either CD300a, or against CD300c were un-
able to discriminate between the two members [19]. Whether the
activating and the inhibitory receptors of this group recognize the
same ligand is still unknown. The CEACAM1 receptor, which inter-
acts homophilically with itself, is another example of paired recep-
tors that do not interact with MHC class I proteins [20]. CEACAM1
was shown to have a shorter, activating version, expressed by T
cells [21]. Whether NK cells also express the short CEACAM1 pro-
tein on their surface is yet unknown.4. Dr. Jekyll and Mr. Hyde: Inhibitory and activating properties
in a single receptor
On top of all of the above examples of paired receptors, proteins
which possess both inhibitory and activating properties also exist.
For example, receptors such as KIR2DL4 and 2B4 are able to trans-
duce both activating and inhibitory signals, depending on the envi-
ronment in which they are acting [22–25]. In the absence of SAP,
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nals, is turning into an inhibitory receptor [24] and KIR2DL4, which
contains only a single ITIM (Table 1), could potentiate or inhibit
various responses depending on whether it is membrane bound
or endocytosed into the cell [26]. Interestingly, the NKp44 activat-
ing receptor, which activates NK cell cytotoxicity through the
usage of the DAP12 adaptor molecule [27], also contains an ITIM
motif, which might be able, under certain circumstances (which
are still unknown), to deliver an inhibitory signal.
All together, it is surprising to notice that the paired receptors
repertoire is actually quite large. However, clearly not all NK cell
receptors come as pairs. The receptors NKG2D, which interacts
with MICA, MICB and ULBP1-6 [28], NKp46 and NKp44 receptors
that recognize various viral hemagglutinins [29,30], NKp30 that
interacts with pp65 of human cytomegalovirus [31], BAT3 [32]
and B7-H6 [33], NKp80 that interacts AICL [34] and the low afﬁnity
Fc receptor CD16 [35] are all powerful killing receptors on NK cells,
lacking inhibitory counterparts. We think that what discriminates
these activating receptors form those who are paired is the
strength of the signal. The activating partner of the paired recep-
tors will always recognize its shared ligand in a lower afﬁnity as
compared to its inhibitory counterpart. We suggest that if a new
activating receptor would be found to have a low afﬁnity interac-
tions with its ligand, inhibitory counterparts might also exist.
Hence, the obvious question is why the previously mentioned
pairs of proteins have developed? It is possible that the paired
receptors have been generated because it might have been easier
to build up two closely related proteins that recognize either dif-
ferent ligands or function differently under certain conditions.
Alternatively, it is possible that the paired receptors indeed bind
the same ligand and that these receptors were developed to ﬁne
tune the delicate balance of NK inhibition and activation. In the
next sections we will elaborate on the function of PVR binding
receptors TIGIT, DNAM1 and CD96 in the ﬁne tuning of NK cell
cytotoxicity.
5. PVR/CD155 and nectin2/CD112
The human nectin family members are Ig-like adhesion mole-
cules that homophilicaly or hetrophilically trans-interact with
each other [36]. Nectin2/CD112 mediates cell to cell adhesion by
either homophilic interaction with nectin2 on a neighboring cell
or through heterophilic interaction with nectin3. Nectin2 is ubiqui-
tously expressed on the surface of cells of various tissues, espe-
cially on epithelial cells, neurons and ﬁbroblasts [36]. CD155 was
originally identiﬁed as the cellular receptor for poliovirus [37]
and therefore it was named polio virus receptor (PVR). Since PVR
shares structural similarity with nectins [36] it was also named
nectin-like molecule-5 (necl-5). Unlike other nectin family mem-
bers, PVR can not interact homophilically with itself. However, it
can heterophilically trans-interact with nectin3 and with the
ECM protein vitronectin for the establishment of adherent junc-
tions [38] and cell-matrix adhesion [39], respectively. PVR is ex-
pressed at low levels in many human cell types of epithelial
origin, and was also detected on monocytes [40]. In mice, PVR is
additionally expressed on many hematopoietic cells [41]. Impor-
tantly, PVR was found to be overexpressed in tumor cell lines
and primary tumors [42–47]. As discussed below, the presence of
PVR on various tumors and on normal cells is also sensed by the
immune system through the usage of the triumvirate receptors
CD96, DNAM1 and TIGIT.
PVR is able to signal and interestingly, it contains an ITIM motif
in its cytoplasmic tail, which may lead to the inhibition of various
processes. Indeed, it was shown that the PVR inhibitory signal
could facilitate cell detachment from extracellular matrix whichleads to cell migration [48]. Additionally, as further discussed be-
low, it was recently demonstrated that PVR could manipulate DC
functions through its interaction with TIGIT on T cells [49]. Surpris-
ingly, engagement of PVR could also lead to activation of some cel-
lular responses as it was demonstrated that PVR is able to augment
cell proliferation which is triggered by growth factors [50]. Thus,
PVR itself could be considered as a member of the ‘‘Dr. Jekyll and
Mr. Hyde” family of receptors. All together, the enhanced PVR
expression by tumor cells enables them to detach, migrate, prolif-
erate, metastasize and also to be recognized by immune cells.
6. PVR and nectin2 are recognized by two co-stimulatory
receptors on NK cells
Members of the nectin family were shown to be recognized by
immune cells [36]. Speciﬁcally, nectin2 has been identiﬁed as a li-
gand for the DNAM1/CD226 receptor, whereas PVR serves as a li-
gand for both DNAM1 and Tactile/CD96 receptors [51,52]. Both
DNAM1 and CD96 are co-stimulating receptors, expressed by cyto-
toxic lymphocytes, act to promote adhesion to ligand-expressing
targets and to enhance the cytolytic capability of NK cells and CTLs
[53–55].
CD96 belongs to the Ig superfamily of receptors and it contains
three IgV like domains. The cytoplasmic domain of CD96 contains a
single putative ITIM motif [52]. However, despite the presence of
an ITIM-like sequence, CD96 engagement does not inhibit NK cell
cytotoxicity, but rather leads to an enhancement of NK cell-medi-
ated tumor lysis, although less efﬁciently than other receptors,
such as DNAM1 [52]. Because CD96 contains an ITIM motif, it
might function as an inhibitory receptor under special, yet un-
known, conditions (perhaps analogous to those of NKp44).
DNAM1 is a transmembrane glycoprotein consisting of an
extracellular region with two IgV-like domains, a transmembrane
region and a cytoplasmic region containing tyrosine- and serine-
phosphorilated sites [56,57]. It is expressed on the majority of
monocytes, T cells and NK cells as well as on small subsets of B
cells [56]. In monocytes, and possibly also in other immune cells,
DNAM1 plays a role in transendothelial migration, where it facili-
tates the adherence to endothelial cells and migration between cell
junctions [58]. DNAM1-deﬁcient mice demonstrated enhanced tu-
mor spread, suggesting that DNAM1 might contribute to tumor
surveillance in vivo [53,59]. However, PVR is also recognized by a
powerful inhibitory receptor, TIGIT, and thus the absence of
DNAM1 might lead to a stronger TIGIT-mediated inhibition of im-
mune cell activities and this could be the primary cause of the en-
hanced tumor spread.
7. TIGIT: a new inhibitory, PVR-binding receptor
TIGIT was ﬁrst identiﬁed by Yu et al. as a surface protein con-
taining an extracellular IgV-like domain, a transmembrane domain
and an intracellular domain which includes one ITIM motif [49]. It
was demonstrated to be expressed on NK cells and on all T cell sub-
sets (including Treg and memory T cells), except for naïve CD4+ T
cells [49]. The receptor was named TIGIT for ‘T cell immunoglobu-
lin and ITIM domain’, however it was later demonstrated to have
an important function in controlling NK activity as well [54].
Therefore, its name seems to be a bit misleading.
Three ligands were identiﬁed for TIGIT: nectin2, nectin3 (which
is still in question [54]) and PVR, which binds TIGIT with the high-
est afﬁnity (Table 1 and [49]). It was suggested that TIGIT on T cells
could not deliver a direct inhibitory signal and that T cells are
inhibited by TIGIT in an indirect manner; through the triggering
of PVR activity in DCs [49]. The engagement of PVR by TIGIT lead
to PVR-mediated signaling that induced IL-10 production by DCs,
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[49]. These observations are quite surprising and are still not com-
pletely understood because it is not clear why the engagement of
PVR by DNAM1 or CD96 would not result in a similar, indirect
inhibitory effect on T cells. On the contrary, DNAM1 was demon-
strated to have activating properties in T cells [60]. Several possible
explanations might be suggested to explain this discrepancy,
which may include either the high binding afﬁnity of TIGIT to
PVR or alternatively, various T cell subsets with different functions.
Shortly after Yu et al. ﬁndings were published, Boles et al. re-
ported about the identiﬁcation of the same receptor, demonstrated
that it binds PVR and named it WUCAM (Washington University
Cell Adhesion Molecule) [61]. Although WUCAM mRNA is ex-
pressed in T and in NK cells, and WUCAM cDNA was even cloned
from NK cells, Boles et al. found that the TIGIT/WUCAM protein
expression is limited to follicular B helper T cells and to a variable
proportion of T and NK cells upon activation. We think that the dis-
crepancy observed in the various works regarding the expression
of TIGIT [49,54,61] is probably due to different mAbs used by the
various groups. Boles et al. showed that PVR is abundantly ex-
pressed by follicular DCs within the germinal center. Hence, it
was suggested that WUCAM/TIGIT-PVR interactions may be impor-
tant in regulating T cell function within the germinal center, con-
tributing to T cell-dependent B cell responses [61]. This
hypothesis was supported by another study demonstrating a de-
fect in IgG and IgA production following orally ingested antigens
in PVR-deﬁcient mice [41]. Thus, TIGIT might have different func-
tions, depending on the cell type being investigated.Fig. 1. The ﬁne tuning model of PVR. (A) Normal healthy cell expresses low levels of PVR.
afﬁnity to PVR among the three PVR-binding receptors and because on normal cells ther
and CD96 probably could not be co-stimulated. (B) In tumors, PVR and for example, the st
when encountering an NK cell, MICA and MICB would trigger the activity of NKG2D. PVR,
would turn towards activation and the malignant target cell would be killed. (C) In viral
miRNA based mechanisms (UL142, UL16 and miR-112). However, PVR expression is only
there will be less activation and consequently less co-stimulation. At the same time, TIGOur group also independently identiﬁed TIGIT (we initially used
the name VSIG9, as appeared in the databases) and also noticed
that it binds PVR and nectin2 [54]. In collaboration with Prof. Jon-
jic’s group we have generated seven monoclonal antibodies direc-
ted against TIGIT and in agreement with the results of Yu et al., we
observed that TIGIT is expressed by many T cell subsets as well as
by NK cells [54]. We demonstrated that TIGIT engagement on NK
cells leads to an ITIM-mediated inhibition, via the use of a yet un-
known phosphatase and further showed that TIGIT binds PVR and
nectin2 but not nectin3 [54]. Importantly, we have shown that
TIGIT, together with MHC class I-speciﬁc inhibitory receptors,
protects primary ﬁbroblasts from NK mediated killing. Thus, we
suggested that TIGIT-PVR interaction may provide an ‘‘alternative
self” mechanism for MHC class I inhibition that might be important
under special conditions, perhaps when NK cells extravasate to
infected tissues.
8. PVR-binding receptors: triumvirate control
As opposed to all other paired receptors mentioned above (pos-
sibly with the exception of KIR2DL2, KIR2DS2 and KIR2DL3 that
bind HLA-C with Asn80, Table 1), PVR is actually recognized by
three different receptors; two co-stimulating receptors (CD96
and DNAM1) and one inhibitory receptor (TIGIT). All three recep-
tors seemed to be expressed by all NK cells (including the CD16-
and CD16+ NK cells in the blood) and the expression of all of them
was not signiﬁcantly altered following IL-2 activation [54]. It will
be interesting to test whether the expression of all of the triumvi-When it encounters an NK cell, inhibition is dominant, because TIGIT has the highest
e is little or no upregulation of ligands for other activating receptors, hence DNAM1
ress induced ligands MICA and MICB, are upregulated. Thus, under these conditions,
at the same time, would be recognized by DNAM1 and CD96. The balance of signals
infections such as HCMV, MICA and MICB are downregulaed by viral protein and by
partially down regulated (by the viral protein UL141). Thus, during HCMV infection,
IT-mediated inhibition will prevail due to its high afﬁnity to PVR.
N. Stanietsky, O. Mandelboim / FEBS Letters 584 (2010) 4895–4900 4899rate PVR binding receptors is different among various NK subsets
such as decidual, endometrial, lymph nodes, tonsils and IL-22 pro-
ducing NK cells, and whether various stimuli, other than IL-2, will
differentially affect the expression of the various PVR-binding
receptors.
Since all of the PVR-binding receptors bind the same ligand, al-
beit with different afﬁnities, our suggestion is that one of the pri-
mary functions of these receptors is to ﬁne tune immune cells’
activities. However, it would be exciting to test whether these
three receptors will additionally affect the other PVR activities
mentioned above, which are not immune related (detachment,
migration and proliferation).
We suggest the following model for the ﬁne tuning of NK cyto-
toxicity by the triumvirate PVR binding receptors (Fig. 1), which
might apply to other immune cells’ activities as well. Under normal
conditions (Fig. 1A), PVR is expressed at low levels on many normal
healthy cells, helping them to establish adherent junctions. Despite
its low level of expression, PVR could probably be recognized by
the inhibitory TIGIT (due to the high binding afﬁnity of TIGIT and
PVR) and thus the killing of self cells is prevented (although all
NK cells express also the PVR-binding, co-stimulatory receptors
DNAM1 and CD96). When tumors emerge (Fig. 1B), PVR expression
might be up-regulated to enable detachment, migration and prolif-
eration of the developing tumors. The up-regulation of PVR to-
gether with the appearance of tumor-speciﬁc activating ligands,
such as the stress-induced ligands for NKG2D [62], or the B7-H6 li-
gand for NKp30 [33], would now co-stimulate DNAM1 and CD96
and together tip the balance of NK activation towards cytotoxicity
(Fig. 1B).
This model imply that changes in the expression levels of the
PVR binding receptors, or in the expression of PVR itself, would
also affect NK cytotoxicity. Indeed, changes in PVR expression lev-
els were observed following human cytomegalovirus (HCMV)
infection. It was demonstrated that HCMV downregulates PVR
and nectin2 to escape DNAM1 and CD96-mediated killing
[63,64]. However, the downregulation of PVR, as well as of nectin2,
was shown to be partial and not complete [63,64]. Our suggestion
is that such moderate expression of PVR and nectin2 on the in-
fected cell surface is the optimal solution for the virus, not only be-
cause it avoids DNAM1 and CD96 recognition but also because it
might still permit the binding of the inhibitory, high afﬁnity,
PVR-binding receptor, TIGIT (Fig. 1C).
In summery, the surprisingly large repertoire of paired recep-
tors expressed by NK cells makes this family of receptors a prom-
inent one in controlling NK activities. It is therefore surprising to
see how little we know about the function of many members of
this family. One of the reasons might be that many of the ligands
of the paired receptors are still unknown. For better understanding
of the paired receptors’ function a comprehensive in vivo study is
needed (in cases where the receptors are shared between human
and mice). Additionally, we need to better characterize the expres-
sion patterns of the paired receptors, their ligands, their binding
afﬁnities, their function on various immune cells and their cooper-
ation with other receptors. All of this will lead to a better under-
standing of the biological functions of the paired receptors.
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